You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
加科思-B(01167.HK)公佈中期業績:上半年研發開支增長71.4%
格隆匯 08-31 21:50

格隆匯8月31日丨加科思-B(01167.HK)公佈中期業績,截至2021年6月30日止六個月,集團錄得收入人民幣5770萬元,這歸因於與AbbVie簽訂以研發、製造及商業化SHP2抑制劑的許可及合作協議所產生的研發成本報銷。

集團的研發開支由截至2020年6月30日止六個月的人民幣7100萬元增加了人民幣5070萬元或71.4%至截至2021年6月30日止六個月的人民幣1.217億元,主要是由於臨牀前候選藥物研發活動的進展及隨相關研發部門擴張而增加的員工成本。

集團致力於成為一家擁有全球市場份額的創新生物製藥公司。為達到此目標,集團計劃全面發展自身能力,包括在中國研發、製造和商業化,以及通過與領先跨國公司合作獲取國際市場份額。集團努力部署集團的創新引擎,打造一個強大的產品管線,在與癌症抗爭的道路上為全球患者帶來幫助。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account